Release Date: February 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

• The aesthetics market in the US is experiencing some softening, which could affect future growth prospects for Dysport.

• Ipsen SA (IPSEF) anticipates a contraction in core operating profit margin in 2025 due to increased R&D expenses and competitive pressures.

: Could you provide more details on the expected erosion pattern for Somatuline in 2025 and the current state of generic competition in Europe and the US? : David Loew, CEO: The erosion pattern for Somatuline is expected to accelerate compared to historical levels due to anticipated market entry by additional generics, likely around mid-year. In Europe and the US, we have seen significant shortages from existing generics, but we expect increased competition and accelerated erosion moving forward.